Therapeutic HIV Vaccines: Post-Infection Immunotherapy and the Path to a Functional Cure

1. Introduction: Prevention Vaccines Versus Post-Infection Vaccines

Vaccines against infectious diseases are usually understood as preventive: they are given before exposure and trained to stop infection or disease. HIV vaccine research has pursued that goal for decades, with largely disappointing results. A parallel and often underappreciated effort runs in the opposite direction: therapeutic vaccination, in which a vaccine is given to people already living with HIV with the aim of teaching their immune system to control the virus without continuous antiretroviral therapy (ART). This article examines that second strategy — its rationale, the platforms tested, the trials conducted, and the gap between early signals and proven benefit.

The distinction matters because the endpoints are different. A preventive vaccine is judged by whether it reduces the acquisition of infection. A therapeutic vaccine is judged by whether it can reduce the latent reservoir, delay or prevent viral rebound after ART interruption, or lower the viral-load setpoint — ideally producing a «functional cure,» a state of durable viral control without ongoing therapy. No therapeutic HIV vaccine has yet achieved that goal, and none is licensed. There is currently no licensed HIV vaccine of any kind.

2. The Conceptual Basis: What a Therapeutic Vaccine Must Accomplish

2.1. The Reservoir Problem

ART blocks viral replication but cannot eliminate the latent reservoir: integrated provirus in resting memory CD4+ T cells that produce no viral proteins and therefore escape both drugs and immune detection. When ART is stopped, these cells reactivate and seed rapid viral rebound within days to weeks. A therapeutic vaccine would need to strengthen immune control sufficiently that this rebound is either prevented or held at a harmless level. That is a high bar: it requires not merely more HIV-specific T cells, but T cells that can recognize conserved viral epitopes, traffic to tissue reservoirs, resist exhaustion, and kill infected cells efficiently.

2.2. Analytical Treatment Interruption (ATI)

The standard experimental design for therapeutic vaccines is the analytical treatment interruption (ATI). Participants are vaccinated while on suppressive ART, then ART is paused under close monitoring. Investigators measure the time to viral rebound, the peak and setpoint viral load, and changes in reservoir markers (for example, total and intact proviral DNA) and HIV-specific immune responses. ATI is scientifically informative but ethically delicate, since it temporarily exposes participants to uncontrolled viremia; modern trials use strict stopping criteria and often resume ART at defined viral-load thresholds. Interpretation must account for the fact that some people who started ART very early — the «post-treatment controllers,» exemplified by the French VISCONTI cohort — can control viremia after interruption even without any vaccine. [Exact cohort figures to be verified.]

3. Vaccine Platforms and Approaches

Therapeutic HIV vaccine candidates have used nearly every modern vaccine technology. Each platform trades off immunogenicity, manufacturing complexity, and safety differently.

3.1. Whole-Inactivated Virus

The oldest approach uses killed or inactivated whole virus, sometimes depleted of certain antigens. The rationale is to present a broad array of viral proteins to the immune system. The flagship example is the HIV-1 immunogen known as Remune. Whole-inactivated vaccines are safe but historically weak at eliciting the kind of potent, broadly functional T-cell responses needed to control an established infection.

3.2. Recombinant Proteins

Recombinant subunit vaccines use one or a few purified viral proteins as immunogens, most often the envelope glycoprotein gp120 or gp140. They are well tolerated and easy to manufacture, but envelope proteins are highly variable and, used alone, tend to elicit antibodies that do not neutralize diverse HIV strains. As therapeutic agents they have generally failed to reduce viral load or reservoir.

3.3. DNA Vaccines

DNA vaccines deliver plasmid-encoded viral antigens that are expressed in the vaccinee’s own cells, theoretically driving both antibody and T-cell responses. A key advantage is the ability to encode conserved or bioinformatically optimized sequences. Their weakness is low immunogenicity in humans; they are often paired with adjuvants, electroporation, or a viral-vector boost.

3.4. Viral Vectors

Viral vectors are the workhorses of T-cell-inducing vaccines. In HIV, the most studied include:

• Modified vaccinia Ankara (MVA). A poxvirus vector that efficiently boosts T-cell responses; widely used in heterologous prime-boost regimens (for example, DNA or ChAd prime followed by MVA boost).
• Vesicular stomatitis virus (VSV). A vector that can be engineered to express HIV antigens and has been explored in both preventive and therapeutic settings.
• Human and rhesus cytomegalovirus (CMV). A remarkable preclinical result in rhesus macaques found that a CMV-based vector expressing SIV antigens could lead to durable control or clearance of a highly pathogenic SIV challenge in a substantial fraction of animals. This result remains the strongest preclinical theme for T-cell-based control, but it has not been translated into a proven human therapeutic or preventive vaccine. [Specific macaque outcomes and protection rates marked for verification.]

Numerous human trials have used adenovirus vectors, including the serotype 5 (Ad5) platform that famously failed (Section 4.3).

3.5. Dendritic-Cell Vaccines

Dendritic cells (DCs) are the professional antigen-presenting cells that orchestrate T-cell immunity. In DC vaccination, a patient’s own monocytes are collected, differentiated into DCs, loaded with HIV antigens — often autologous virus or viral RNA from the same patient — and reinfused. The approach is exquisitely personalized and scientifically appealing, and small trials have reported transient viral-load reductions and increases in HIV-specific T-cell responses. But manufacturing is complex, expensive, and hard to scale.

3.6. Conserved-Region and Epitope Vaccines

Because the viral envelope mutates rapidly, many groups have focused instead on conserved regions of the HIV proteome — sequences that the virus cannot easily change without losing fitness. By steering the immune response toward these regions, the hope is to overcome HIV’s sequence diversity. Notable examples include the HIVconsv immunogens (which fuse conserved segments from Gag, Pol, Vif, and Env) and conserved «mosaic» antigens. These have reproducibly induced HIV-specific T cells in early trials; whether that translates into control during ATI is the open question.

3.7. mRNA Platforms

mRNA vaccines, validated at scale by the COVID-19 pandemic, are being explored for HIV in both preventive and therapeutic settings. Their flexibility would permit rapid encoding of conserved or personalized antigen sets. As of current knowledge, HIV mRNA vaccine candidates remain in early-phase clinical testing, and no efficacy data support them for therapeutic use. [Program status marked for verification.]

4. Representative Trials and Their Lessons

4.1. Remune (HIV-1 Immunogen)

Remune was an inactivated, gp120-depleted HIV-1 immunogen developed in the 1990s. Despite early enthusiasm, controlled trials — including large randomized studies in people with preserved CD4 counts — failed to show a significant clinical benefit on viral load, CD4 decline, or disease progression. It became a textbook example of a well-tolerated therapeutic vaccine that did not work. [Exact trial sizes and primary endpoints to be verified.]

4.2. Recombinant gp120 Trials

Recombinant gp120 was tested both as a preventive vaccine (notably in the AIDSVAX program) and in therapeutic settings. As preventive immunogens they showed essentially no efficacy in the key efficacy trials; as therapeutic immunogens they likewise failed to produce meaningful virologic control. The experience demonstrated that antibody responses against a single envelope protein are insufficient against a virus as diverse and evasive as HIV.

4.3. MRKAd5 and the Adenovirus Lesson

The Merck Ad5 trivalent vaccine (expressing Gag, Pol, and Nef) was the centerpiece of the STEP trial, a large preventive efficacy study. It was halted in 2007 after interim analysis showed not only futility but a signal of increased HIV acquisition among Ad5-seropositive men. A parallel South African trial (Phambili) was also stopped. The vector induced HIV-specific T cells yet failed to protect, and the unexpected harm signal forced a deep reappraisal of T-cell vaccines. Ad5-based therapeutic approaches met similar disappointment. The episode is one of the most important cautionary tales in the field.

4.4. Dendritic-Cell Vaccination Trials

Several small academic trials have vaccinated patients with autologous DCs pulsed with autologous inactivated virus or antigens. These studies reported increased HIV-specific T-cell responses and, in some participants, transient reductions in viral load during ATI. The trials were small, often uncontrolled or with heterogeneous designs, and the effects were not durable. They remain a promising but unproven strategy.

4.5. AGS-004

AGS-004 was an autologous DC product transfected with the patient’s own HIV antigen-encoding RNA, designed to elicit personalized HIV-specific immunity. A randomized Phase 2 trial combined it with ATI. Results were modest: some participants showed transient effects on viral load, but there was no consistent, durable control of rebound, and the program was discontinued. It illustrates both the appeal and the difficulty of personalized cell-based therapeutic vaccines. [Detailed results to be verified.]

4.6. Conserved-Region Immunogens

Prime-boost regimens built around HIVconsv (for example, a chimpanzee adenovirus prime followed by an MVA boost) have consistently induced high-frequency HIV-specific T cells targeting conserved regions. However, in ATI studies these responses have generally not prevented viral rebound; at best they have been associated with modest changes in viral dynamics. The gap between immunogenicity and virologic control is the central unresolved problem of therapeutic vaccination.

4.7. Summary of the Evidence

5. Why Results Have Been Modest: Immune Correlates and Exhaustion

The recurring theme is that vaccines can induce HIV-specific T cells without achieving virologic control. Several explanations are supported by the literature:

• T-cell exhaustion. Chronic antigen exposure drives expression of inhibitory receptors such as PD-1, TIM-3, and LAG-3, and impairs the proliferative and cytotoxic capacity of HIV-specific CD8+ T cells. A vaccine given on top of an exhausted T-cell compartment may not restore function.
• Insufficient breadth and specificity. Responses skewed away from conserved Gag epitopes, or too narrow to cover escape variants, leave the virus room to evade. Broad Gag-specific responses correlate with better natural control in elite controllers, suggesting that specificity matters as much as magnitude.
• Reservoir inaccessibility. Even functional CD8+ T cells may not reach the anatomical and cellular sanctuaries where latent virus persists. Vaccination alone does not reactivate latent provirus, so infected cells remain invisible to cytotoxic T cells.
• Immune activation and inflammation. Persistent inflammation and microbial translocation (see the companion article on the gut microbiome) undermine the quality of vaccine-induced immunity.

6. Combination Strategies: Beyond Vaccine Alone

The prevailing view is that therapeutic vaccination will not succeed in isolation and must be combined with other interventions:

• Latency-reversing agents (LRAs). The «shock and kill» concept pairs an LRA — such as an HDAC inhibitor (vorinostat, romidepsin), disulfiram, or a PKC agonist — with an immune effector, often a vaccine or an antibody, to reactivate latent virus and then eliminate the newly exposed infected cells. Results to date have shown reservoir perturbation at most, without a durable cure. [Marked for verification regarding specific LRA trial outcomes.]
• Broadly neutralizing antibodies (bNAbs). bNAbs such as VRC01 and 3BNC117 can suppress viremia during ATI and may enhance immune control. Combining bNAbs with vaccines is an active research direction in both prevention (the AMP trials for VRC01) and therapy. In the AMP prevention trials, VRC01 did not prevent overall HIV acquisition but did show efficacy against VRC01-sensitive strains — an instructive partial result.
• Immune modulators and checkpoint blockade. Agents that reduce T-cell exhaustion or boost innate immunity are being tested alongside vaccines (see the companion article on immune-based therapies).

7. Distinguishing Early Signals from Proven Benefit

A recurring problem in this field is the enthusiastic reporting of immunogenicity as if it were efficacy. A vaccine that increases HIV-specific T-cell frequencies by several-fold has demonstrated a mechanistic effect, not a clinical one. Durable benefit would require, at minimum, a reproducible delay in rebound that persists across trials, a lowering of the viral-load setpoint, or a reduction in reservoir size that is confirmed by multiple standardized assays. As of current knowledge, no therapeutic HIV vaccine has met those criteria. Claims of a «functional cure» from vaccination remain unsupported.

It is equally important to avoid the opposite error — dismissing the field entirely. The VISCONTI post-treatment controllers prove that durable ART-free remission is biologically possible in some people, and the CMV-vector macaque data show that powerful T-cell control is achievable in principle. These are genuine scientific anchors. But they are proof of possibility, not of a deliverable product.

8. Conclusion

Therapeutic HIV vaccines aim to convert a chronic, ART-dependent infection into a controlled state that requires little or no ongoing treatment. Three decades of testing have produced a clear but sobering picture: most platforms are safe, many induce measurable HIV-specific immune responses, and none has delivered durable virologic control. Whole-inactivated virus (Remune), recombinant gp120, and adenoviral-vector vaccines all failed their key tests; dendritic-cell and conserved-region approaches show intriguing but transient signals; mRNA and CMV-vector concepts remain experimental. The bottleneck is not immunogenicity but the ability to translate new T-cell responses into control of a latent, diverse, and immune-evasive reservoir.

The most plausible path forward is combination therapy: a vaccine to supply effectors, an LRA to expose the reservoir, and bNAbs or immune modulators to press the advantage. Until such combinations demonstrate reproducible, durable control in randomized trials, therapeutic HIV vaccination should be described as an active area of research — scientifically valuable, honestly reported, and not yet a cure.

Sources and Key Research Centers

1. National Institute of Allergy and Infectious Diseases (NIAID), NIH — Principal funder of HIV vaccine research and of the clinical trials networks that conduct preventive and therapeutic vaccine studies.
2. HIV Vaccine Trials Network (HVTN) — The largest global clinical trials network dedicated to HIV vaccine development, including therapeutic vaccine and ATI studies (for example, the STEP/HVTN 502 trial).
3. International AIDS Vaccine Initiative (IAVI) — Nonprofit scientific organization advancing HIV vaccine design, including conserved-region and germline-targeting immunogens.
4. International AIDS Society (IAS) — Towards an HIV Cure — Coordinates global cure research priorities, including therapeutic vaccination and analytical treatment interruption methodology.
5. The New England Journal of Medicine — Publishes landmark HIV prevention and treatment trials (for example, the AMP broadly neutralizing antibody trials). [Citation details to be verified.]
6. Nature Medicine — Peer-reviewed journal that published key dendritic-cell vaccine and cure-related research. [Specific article citations to be verified.]
7. The Lancet HIV — Dedicated HIV clinical research journal covering therapeutic vaccine trials and ATI studies.
8. The Journal of Infectious Diseases — Publisher of therapeutic vaccine and HIV immunology studies.
9. University of Oxford (Jenner Institute / Nuffield Department of Medicine) — Home of the HIVconsv conserved-region immunogen program and related prime-boost vaccine trials. [Citation details to be verified.]
10. Fred Hutchinson Cancer Center — A hub for HIV vaccine and cure research, including HVTN coordination and computational immunology.
11. Oregon Health & Science University (OHSU), Vaccine and Gene Therapy Institute — Associated with the cytomegalovirus-vector SIV vaccine research in nonhuman primates. [Citation details to be verified.]
12. Centers for Disease Control and Prevention (CDC), Division of HIV Prevention — Public-health context for HIV prevention and treatment.
13. World Health Organization (WHO) — Global HIV treatment and prevention guidelines.
14. UNAIDS — Global epidemiological data on HIV burden and treatment coverage.
15. ClinicalTrials.gov (US National Library of Medicine) — Registry of therapeutic HIV vaccine and ATI trials. [Specific NCT numbers to be verified.]
16. US Food and Drug Administration (FDA) — Regulatory authority for vaccine licensure; no therapeutic HIV vaccine is currently approved.